ADCT
ADC Therapeutics S.A.
There isn't enough reported data to score ADCT yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ADCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
ADCT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ADCT PE Valuation
ADCT has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ADCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ADCT's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ADCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.53 | +$0.89 |
| Q2 2026 | -$0.67 | +$0.87 |
| Q1 2026 | -$1.06 | +$0.36 |
| Q4 2025 | -$1.21 | +$0.41 |
| Q3 2025 | -$1.42 | +$0.97 |
| Q2 2025 | -$1.54 | +$1.01 |
| Q1 2025 | -$1.42 | +$1.33 |
| Q4 2024 | -$1.62 | +$1.30 |
ADCT is still losing money, but far less than before: $0.53 per share over the past year, against $3.71 at its worst in late 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ADCT on earnings quality, reporting a profit while its opponent remains loss making.
ADCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $21.7M | +32% |
| Q2 2026 | $19.2M | +2.2% |
| Q1 2026 | $20.9M | -9.5% |
| Q4 2025 | $23.1M | +36% |
| Q3 2025 | $16.4M | -11% |
| Q2 2025 | $18.8M | +8.2% |
| Q1 2025 | $23M | +28% |
| Q4 2024 | $16.9M | +0.7% |
ADCT's revenue is recovering but still below its 2022 peak: $22M last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -66% | +122 points |
| Q2 2026 | -132% | +102 points |
| Q1 2026 | -121% | +2.5 points |
| Q4 2025 | -78% | +114 points |
| Q3 2025 | -189% | +4.1 points |
| Q2 2025 | -234% | -68 points |
| Q1 2025 | -124% | +63 points |
| Q4 2024 | -192% | +46 points |
ADCT's operating margin was −66% last quarter, up 122 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ADCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ADCT on profitability, with a higher operating margin.
ADCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.9M | +$1.8M |
| Q2 2026 | -$11.8M | +$12.3M |
| Q1 2026 | -$29.7M | +$26.9M |
| Q4 2025 | -$31.1M | -$9.2M |
| Q3 2025 | -$29.6M | -$4.4M |
| Q2 2025 | -$24.1M | +$8.8M |
| Q1 2025 | -$56.6M | -$12M |
| Q4 2024 | -$21.9M | +$11.1M |
ADCT has burned cash in almost every quarter: −$101M over the past year, against −$132M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ADCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
ADCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +394K shares |
| 1 year | +14% | +19M shares |
| 3 years | +89% | +73.2M shares |
| 5 years | +103% | +78.7M shares |
| Available history | +112% | +82.2M shares |
ADCT has 155M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $218,871 |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ADCT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ADCT Net Leverage
ADCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ADCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 61.0 | Neutral |
ADCT's weekly RSI is 44 (neutral) and its Stochastic is 61 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ADCT PE vs Healthcare Sector
ADCT has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ADCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.44 | 2.1% below |
| 20 week MA | $1.26 | 12% above |
| 50 week MA | $2.55 | 45% below |
| 100 week MA | $2.60 | 46% below |
| 200 week MA | $2.64 | 47% below |
ADCT's trend is mixed: it's above one of its five weekly moving averages, and 47% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ADCT on trend strength, trading above more of its moving averages.
ADCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.7 | $37.0 | +25% |
| 2021 | $37.0 | $21.3 | -43% |
| 2022 | $21.3 | $3.52 | -83% |
| 2023 | $3.52 | $1.66 | -53% |
| 2024 | $1.66 | $2.03 | +22% |
| 2025 | $2.03 | $3.51 | +73% |
| 2026 YTD | $3.51 | $1.41 | -60% |
ADCT has finished lower in three of the last six years. It's down 60% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ADCT on returns for 2026, with the stronger performance.